Elusys Therapeutics, Inc.
about us technology product pipeline news&events careers
Elusys Overview Leadership Biodefense Corporate Fact Sheet
Executive Team Board of  Directors Scientific Advisory Board
Technology Heteropolymer Antibodies CR1 Vaccines Publications
Overview Process Animation
Antibody Heteropolymers Antigen Heteropolymers Anthrax Antibody
Pipeline Anthim Anthrax Antibody Staph A HP - ETI-211 Candida HP CR1 Vaccines
Press Releases Presentations
Our Values Working at Elusys Open Positions Benefits Location

NEWS & EVENTS

PRESS RELEASES 2004

2007   2006   2005   2004

 

November 1st, 2004


Elusys Therapeutics Presents Staphylococcus Aureus Data at iCAAC

 

October 13th, 2004

 

 

Elusys Therapeutics Receives Broad Government Funding to Continue Development of Anti-Anthrax Drug

 

August 2nd, 2004

Elusys Therapeutics Completes Round of Private Financing

 

July 23rd, 2004

 

Elusys Therapeutics Announces Reorganization

 

May 5th, 2004

 

Elusys Therapeutics Anthrax Product Selected for Testing by Federal Government

 

March 8th, 2004

 

Elusys Presents Data on Anthrax Antibody at American Society for Microbiology’s Biodefense Research Meeting

 

February 20th, 2004

 

 

Elusys Therapeutics to Present at Bio CEO and Investor Conference

 

 

 

 

 

 

 

 

  • Copyright© 2008 Elusys Therapeutics, Inc. All Rights Reserved.
  • contact us
  • site map
  • careers